Madrigal Pharmaceuticals, Inc. (MDGL)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 180 | 958 | 1,284 | 1,524 |
| Operating profit | $m | -300 | -323 | ||||||
| Net profit | $m | -202 | -242 | -295 | -374 | -466 | -288 | -325 | -193 |
| EPS reported | $ | -12.85 | -12.89 | ||||||
| Operating cashflow per share | $ | -8.45 | -6.78 | ||||||
| Capex per share | $ | 0.02 | 0.29 | ||||||
| FCF per share | $ | -8.47 | -7.08 | ||||||
| Free cash flow | $m | -190 | -206 | ||||||
| Net debt | $m | -636 | -498 | ||||||
| Book value equity | $m | 603 | 524 | ||||||
| Book value per share | $ | 26.86 | 17.97 | ||||||
| Number of shares | m | 22.43 | 29.15 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 21.68 | 24.95 | ||||||
| P/S LTM | x | 13.63 | 10.18 | ||||||
| P/FCF LTM | x | -68.75 | -63.33 | ||||||
| EV/EBITDA LTM | x | -49.99 | -44.25 | ||||||
| EV/Sales LTM | x | 13.79 | 9.18 | ||||||
| Earnings Yield LTM | % | -2.21% | -2.20% | ||||||
| FCF Yield | % | -1.45% | -1.58% | ||||||
| Quality | |||||||||
| ROE | % | -47.83% | -56.65% | ||||||
| ROIC | % | -31.58% | -37.02% | ||||||
| Operating margin | % | -31.31% | -25.13% | ||||||
| Gross margin | % | +94.14% | +91.48% | ||||||
| FCF/Sales | % | -19.83% | -16.07% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +432.05% | +612.77% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.54 | -0.59 | ||||||
| Net Debt/EBITDA | x | -0.59 | -0.18 | ||||||
| EBIT/Net interest | x | -13.45 | -20.64 | ||||||
| Net debt/market cap | % | +2.66% | +2.91% | ||||||
| Net debt/Equity | x | -1.06 | -0.95 | ||||||
| Gross debt/equity | x | 0.59 | 0.66 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Madrigal Pharmaceuticals, Inc. (MDGL)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free